PRESS RELEASES
<< Back
Xcel Brands, Inc. Announces First Quarter 2025 Financial Results, Shows Continued Improvements in Operating Results as a Result of Its “Project Fundamentals” Restructuring Program
- First quarter 2025 net loss of
$2.8 million , representing a 56% improvement from the prior year quarter net loss of$6.3 million . - Net loss on a non-GAAP basis was
$1.4 million for the first quarter 2025, representing a 24% improvement from the first quarter of 2024 non-GAAP net loss of$1.8 million . - Adjusted EBITDA for the first quarter 2025 was negative
$0.7 million , compared with Adjusted EBITDA of negative$1.6 million for the first quarter 2024, representing a 56% improvement.
First Quarter 2025 Financial Results
Total revenue for the first quarter of 2025 was
Direct operating costs and expenses decreased approximately
Net loss attributable to
After adjusting for certain cash and non-cash items, results on a non-GAAP basis were a net loss of approximately
Adjusted EBITDA also improved on a year-over-year basis, from negative
Balance Sheet
The Company's balance sheet at
In
Conference Call and Webcast
The Company will host a conference call with members of the executive management team to discuss these results and together with the fourth quarter and fiscal year 2024 results. Details of the date and time of this call will be released shortly.
About
Forward Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical fact contained in this press release, including statements regarding future events, our future financial performance, business strategy and plans and objectives of management for future operations, are forward-looking statements. We have attempted to identify forward-looking statements by terminology including "anticipates," "believes," "can," "continue," "ongoing," "could," "estimates," "expects," "intends," "may," "appears," "suggests," "future," "likely," "goal," "plans," "potential," "projects," "predicts," "seeks," "should," "would," "guidance," "confident" or "will" or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements regarding our anticipated revenue, expenses, profitability, strategic plans and capital needs. These statements are based on information available to us on the date hereof and our current expectations, estimates and projections and are not guarantees of future performance. Forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors, including, without limitation, the risks discussed in the "Risk Factors" section and elsewhere in the Company's Annual Report on form 10-K for the year ended
For further information please contact:
sburroughs@xcelbrands.com
Non-GAAP net income and non-GAAP diluted EPS are non-GAAP unaudited terms. We define non-GAAP net income as net income (loss) attributable to
Adjusted EBITDA is a non-GAAP unaudited measure, which we define as net (loss) income attributable to
Management uses non-GAAP net income, non-GAAP diluted EPS, and Adjusted EBITDA as measures of operating performance to assist in comparing performance from period to period on a consistent basis and to identify business trends relating to our results of operations. Management believes non-GAAP net income, non-GAAP diluted EPS, and Adjusted EBITDA are also useful because these measures adjust for certain costs and other events that management believes are not representative of our core business operating results, and thus these non-GAAP measures provide supplemental information to assist investors in evaluating our financial results.
Non-GAAP net income, non-GAAP diluted EPS, and Adjusted EBITDA should not be considered in isolation or as alternatives to net income, earnings per share, or any other measure of financial performance calculated and presented in accordance with GAAP. Given that non-GAAP net income, non-GAAP diluted EPS, and Adjusted EBITDA are financial measures not deemed to be in accordance with GAAP and are susceptible to varying calculations, our non-GAAP net income, non-GAAP diluted EPS, and Adjusted EBITDA may not be comparable to similarly titled measures of other companies, including companies in our industry, because other companies may calculate these measures in a different manner than we do. In evaluating non-GAAP net income, non-GAAP diluted EPS, and Adjusted EBITDA, you should be aware that in the future we may or may not incur expenses similar to some of the adjustments in this document. Our presentation of non-GAAP net income, non-GAAP diluted EPS, and Adjusted EBITDA does not imply that our future results will be unaffected by these expenses or any unusual or non-recurring items. When evaluating our performance, you should consider non-GAAP net income, non-GAAP diluted EPS, and Adjusted EBITDA alongside other financial performance measures, including our net income and other GAAP results, and not rely on any single financial measure.
| Unaudited Consolidated Statements of Operations | |||||||
| (in thousands, except share and per share data) | |||||||
| For the Three Months Ended | |||||||
| 2025 | 2024 | ||||||
| Revenues | |||||||
| Net licensing revenue | $ | 1,332 | $ | 2,184 | |||
| Operating costs and expenses | |||||||
| Salaries, benefits and employment taxes | 1,086 | 1,933 | |||||
| Other selling, general and administrative expenses | 1,197 | 2,029 | |||||
| Total direct operating costs and expenses | 2,283 | 3,962 | |||||
| Other expense, including non-cash expenses | |||||||
| Depreciation and amortization | 900 | 1,589 | |||||
| Asset impairment charges | - | 2,295 | |||||
| Loss from equity method investment | 576 | 533 | |||||
| Change in contingent reduction in equity ownership of |
(240 | ) | - | ||||
| Operating loss | (2,187 | ) | (6,195 | ) | |||
| Interest and finance expense | |||||||
| Interest expense | 473 | 146 | |||||
| Other interest and finance charges | 87 | 4 | |||||
| Total interest and finance expense | 560 | 150 | |||||
| Loss before income taxes | (2,747 | ) | (6,345 | ) | |||
| Income tax provision (benefit) | 50 | - | |||||
| Net loss | (2,797 | ) | (6,345 | ) | |||
| Less: Net loss attributable to noncontrolling interest | - | (51 | ) | ||||
| Net loss attributable to |
$ | (2,797 | ) | $ | (6,294 | ) | |
| Loss per common share attributed to |
|||||||
| Basic and diluted net loss per share | $ | (1.18 | ) | $ | (3.09 | ) | |
| Weighted average number of common shares outstanding: | |||||||
| Basic and diluted weighted average common shares outstanding | 2,373,583 | 2,037,397 | |||||
| Unaudited Consolidated Balance Sheets | ||||||||
| (in thousands, except share and per share data) | ||||||||
| Assets | ||||||||
| Current Assets: | ||||||||
| Cash and cash equivalents | $ | 298 | $ | 1,254 | ||||
| Accounts receivable, net | 2,105 | 2,269 | ||||||
| Prepaid expenses and other current assets | 508 | 520 | ||||||
| Total current assets | 2,911 | 4,043 | ||||||
| Property and equipment, net | 180 | 182 | ||||||
| Operating lease right-of-use assets | 3,573 | 3,751 | ||||||
| Trademarks and other intangibles, net | 33,877 | 34,759 | ||||||
| Equity method investment | 9,534 | 10,110 | ||||||
| Other assets | 2411 | 911 | ||||||
| Total non-current assets | 49,575 | 49,713 | ||||||
| Total Assets | $ | 52,486 | $ | 53,756 | ||||
| Liabilities and Stockholders' Equity | ||||||||
| Current Liabilities: | ||||||||
| Accounts payable, accrued expenses and other current liabilities | $ | 2,714 | $ | 2,734 | ||||
| Deferred revenue | 1,398 | 1,380 | ||||||
| Accrued income taxes payable | 546 | 554 | ||||||
| Current portion of operating lease obligation | 1,594 | 1,513 | ||||||
| Current portion of long-term debt | 250 | - | ||||||
| Current portion of contingent obligations | 3,973 | 4,213 | ||||||
| Total current liabilities | 10,475 | 10,394 | ||||||
| Long-Term Liabilities: | ||||||||
| Deferred revenue | 2,444 | 2,667 | ||||||
| Long-term portion of operating lease obligation | 4,956 | 5,297 | ||||||
| Long-term debt, net, less current portion | 8,470 | 6,569 | ||||||
| Other long-term liabilities | 431 | 431 | ||||||
| Total long-term liabilities | 16,301 | 14,964 | ||||||
| Total Liabilities | 26,776 | 25,358 | ||||||
| Commitments and Contingencies | ||||||||
| Stockholders' Equity: | ||||||||
| Preferred stock, |
- | - | ||||||
| Common stock, |
2 | 2 | ||||||
| Paid-in capital | 106,775 | 106,666 | ||||||
| Accumulated deficit | (79,041 | ) | (76,244 | ) | ||||
| 27,736 | 30,424 | |||||||
| Noncontrolling interest | (2,026 | ) | (2,026 | ) | ||||
| Total Stockholders' Equity | 25,710 | 28,398 | ||||||
| Total Liabilities and Stockholders' Equity | $ | 52,486 | $ | 53,756 | ||||
| Unaudited Consolidated Statements of Cash Flows | ||||||||
| (in thousands) | ||||||||
| For the Three Months Ended | ||||||||
| 2025 | 2024 | |||||||
| Cash flows from operating activities | ||||||||
| Net loss | $ | (2,797 | ) | $ | (6,345 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation and amortization expense | 900 | 1,589 | ||||||
| Asset impairment charges | - | 2,295 | ||||||
| Amortization of deferred finance costs | 102 | 26 | ||||||
| Stock-based compensation and cost of licensee warrants | 109 | 144 | ||||||
| Contingent reduction in equity ownership of |
(240 | ) | - | |||||
| Loss from equity method investment | 576 | 533 | ||||||
| Accounts receivable | 164 | (149 | ) | |||||
| Inventory | - | 8 | ||||||
| Prepaid expenses and other assets | 12 | (156 | ) | |||||
| Deferred revenue | (205 | ) | (223 | ) | ||||
| Accounts payable, accrued expenses and other current liabilities | 27 | (560 | ) | |||||
| Lease-related assets and liabilities | (82 | ) | (237 | ) | ||||
| Other Liabilities | - | 466 | ||||||
| Net cash used in operating activities | (1,434 | ) | (2,609 | ) | ||||
| Cash flows from investing activities | ||||||||
| Purchase of property and equipment | (14 | ) | - | |||||
| Net cash used in investing activities | (14 | ) | - | |||||
| Cash flows from financing activities | ||||||||
| Proceeds from public offering and private placement transactions, net of transaction costs | - | 1,902 | ||||||
| Proceeds from long-term debt | 2,050 | - | ||||||
| Shares repurchased including vested restricted stock in exchange for withholding taxes | (58 | ) | - | |||||
| Net cash provided by (used in) financing activities | 1,992 | 1,902 | ||||||
| Net increase (decrease) in cash and cash equivalents | 544 | (707 | ) | |||||
| Cash and cash equivalents at beginning of period | 1,993 | 2,998 | ||||||
| Cash and cash equivalents at end of period | $ | 2,537 | $ | 2,291 | ||||
| Reconciliation to amounts on consolidated balance sheets: | ||||||||
| Cash and cash equivalents | 298 | 1,552 | ||||||
| Restricted cash (reported in other non-current assets) | 2,239 | 739 | ||||||
| Total cash, cash equivalents, and restricted cash | $ | 2,537 | $ | 2,291 | ||||
| For the Three Months Ended | ||||||||
| ($ in thousands) | ||||||||
| 2025 | 2024 | |||||||
| (Unaudited) | (Unaudited) | |||||||
| Net loss attributable to |
$ | (2,797 | ) | $ | (6,294 | ) | ||
| Asset impairment | - | 2,295 | ||||||
| Amortization of trademarks | 875 | 1,519 | ||||||
| Loss from equity method investments | 576 | 533 | ||||||
| Contingent reduction in equity ownership of |
(240 | ) | - | |||||
| Stock-based compensation and cost of licensee warrants | 166 | 144 | ||||||
| Income tax provision (benefit) | 50 | - | ||||||
| Non-GAAP net (loss) | $ | (1,370 | ) | $ | (1,803 | ) | ||
| For the Three Months Ended | ||||||||
| 2025 | 2024 | |||||||
| (Unaudited) | (Unaudited) | |||||||
| Diluted loss per share attributable to |
$ | (1.18 | ) | $ | (3.09 | ) | ||
| Asset impairment | - | 1.13 | ||||||
| Amortization of trademarks | 0.37 | 0.75 | ||||||
| Loss from equity method investments | 0.24 | 0.26 | ||||||
| Contingent reduction in equity ownership of |
(0.10 | ) | - | |||||
| Stock-based compensation and cost of licensee warrants | 0.07 | 0.07 | ||||||
| Income tax provision (benefit) | 0.02 | - | ||||||
| Non-GAAP diluted EPS | $ | (0.58 | ) | $ | (0.88 | ) | ||
| Non-GAAP weighted average diluted shares | 2,373,583 | 2,037,397 | ||||||
| For the Three Months Ended | ||||||||
| ($ in thousands) | ||||||||
| 2025 | 2024 | |||||||
| (Unaudited) | (Unaudited) | |||||||
| Net loss attributable to |
$ | (2,797 | ) | $ | (6,294 | ) | ||
| Asset impairment | - | 2,295 | ||||||
| Depreciation and amortization | 900 | 1,589 | ||||||
| Loss from equity method investments | 576 | 533 | ||||||
| Contingent reduction in equity ownership of |
(240 | ) | - | |||||
| Interest and finance expense | 560 | 150 | ||||||
| Income tax benefit | 50 | - | ||||||
| State and local franchise taxes | 8 | 12 | ||||||
| Stock-based compensation and cost of licensee warrants | 166 | 144 | ||||||
| Accretion of lease liability for exited lease | 61 | - | ||||||
| Costs associated with restructuring of operations | 17 | - | ||||||
| Adjusted EBITDA | $ | (699 | ) | $ | (1,571 | ) | ||
Source: Xcel Brands, Inc
